Related references
Note: Only part of the references are listed.The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma
D. S. Ritchie et al.
ANNALS OF HEMATOLOGY (2007)
Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas - Results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group
Christina Nickenig et al.
CANCER (2006)
Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma
C Thieblemont et al.
CANCER (2005)
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine
JE Romaguera et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Hematopoietic stem cell transplantation in mantle cell lymphoma
AK Ganti et al.
ANNALS OF ONCOLOGY (2005)
Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network
M Dreyling et al.
BLOOD (2005)
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma:: Results of a prospective randomized trial of the German low grade lymphoma study group (GLSG)
G Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma
YL Kasamon et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2005)
Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis
J Mangel et al.
ANNALS OF ONCOLOGY (2004)
Transplantation in patients with diffuse mantle cell lymphoma in first disease remission the prognostic value of β2-microglobulin and the tumor score
IF Khouri et al.
CANCER (2003)
Primary treatment with autologous stem cell transplantation in mantle cell lymphoma:: outcome related to remission pretransplant
NS Andersen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2003)
Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen)
AM Gianni et al.
BLOOD (2003)
Outcome of autologous transplantation for mantle cell lymphoma:: A study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant registries
E Vandenberghe et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Autologous stem cell transplantation in patients with mantle cell lymphoma
R Oinonen et al.
LEUKEMIA & LYMPHOMA (2002)
High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma
AK Gopal et al.
BLOOD (2002)
Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival
OM Howard et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma
PL Zinzani et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Autologous hematopoietic stem cell transplantation for mantle cell lymphoma
JM Vose et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2000)
Share Paper
